The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Regulatory & Policy

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
Pharma & Human Health

AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244

DEC 9, 2025
MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®
Finance

MaaT Pharma Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg®

JUN 3, 2025
Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims
Editor's Choice

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims

OCT 22, 2024
Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy
Pharma & Human Health

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the FDA for treatment of Duchenne Muscular Dystrophy

SEP 24, 2024
ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®
Basic & Discovery Research

ProDigest Awarded FDA Contract to Provide a Preclinical Gastrointestinal Model: SHIME®

SEP 16, 2024
FDA cracks down on illegal probiotic product usage for hospitalised preterm infants
Pharma & Human Health

FDA cracks down on illegal probiotic product usage for hospitalised preterm infants

NOV 30, 2023
EMA adopts guidelines on veterinary medicinal products for phage therapy.
Animal Health

EMA adopts guidelines on veterinary medicinal products for phage therapy.

OCT 29, 2023
Ensuring standardised data collection for microbiome research, a sit down with DNA Genotek’s Heloise Breton and Austin Udocor
Basic & Discovery Research

Ensuring standardised data collection for microbiome research, a sit down with DNA Genotek’s Heloise Breton and Austin Udocor

JUL 12, 2023
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation
Infectious Disease & AMR

Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation

JUL 5, 2023